Phase I Study of AZD1775 (MK-1775) With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients With Recurrent Glioblastoma
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2017
At a glance
- Drugs AZD-1775 (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- 17 Oct 2017 Status changed from recruiting to suspended.
- 17 Aug 2017 Planned primary completion date changed from 15 Jun 2017 to 15 Aug 2018.
- 10 Jun 2017 Biomarkers information updated